Company / Capital Expenditures
Dyne Therapeutics, Inc. Capital Expenditures History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$2.4M
FY2024
5-year range
$729.0K / $3.6M
FY2020-FY2024
Trend
+225.9%
vs FY2023
Sector context
#91 of 192
Health Care
What the data says
Capital Expenditures changed +226% YoY in FY2024, a notable deviation from the 5-year average annual change of +63%.
Based on SEC 10-K filings.
$2M in FY2024 with a 5-year CAGR of +7.6%.
Declined from $3M to $2M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -13.1%
- 5-Year CAGR
- +7.6%
- 10-Year CAGR
- -
Sector benchmark
#91 of 192 in Health CareTop 47% of 192This company $2.4M Sector average $118.6M
▼
-98.0% below sector average
Key checks
Key Insights
- 5-year CAGR of +7.6%, indicating consistent growth.
- In FY2024, capital expenditures increased 225.9% year-over-year.
- Ranks #91 out of 192 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score 3.40 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $2.4M | +225.9% |
| FY2023 | $729.0K | -76.2% |
| FY2022 | $3.1M | -15.2% |
| FY2021 | $3.6M | +211.6% |
| FY2020 | $1.2M | -29.5% |
| FY2019 | $1.6M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026